Advertisement

Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis

Published:August 24, 2015DOI:https://doi.org/10.1016/j.rdc.2015.07.002

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Rheumatic Disease Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chandran V.
        • Schentag C.T.
        • Brockbank J.E.
        • et al.
        Familial aggregation of psoriatic arthritis.
        Ann Rheum Dis. 2009; 68: 664-667
        • Nair R.P.
        • Stuart P.E.
        • Nistor I.
        • et al.
        Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene.
        Am J Hum Genet. 2006; 78: 827-851
        • Eder L.
        • Chandran V.
        • Pellett F.
        • et al.
        Differential human leucocyte allele association between psoriasis and psoriatic arthritis: a family-based association study.
        Ann Rheum Dis. 2012; 71: 1361-1365
        • Gudjonsson J.E.
        • Karason A.
        • Runarsdottir E.H.
        • et al.
        Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients–an analysis of 1019 HLA-C- and HLA-B-typed patients.
        J Invest Dermatol. 2006; 126: 740-745
        • Eder L.
        • Chandran V.
        • Gladman D.D.
        What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?.
        Curr Opin Rheumatol. 2015; 27: 91-98
        • Winchester R.
        • Minevich G.
        • Steshenko V.
        • et al.
        HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype.
        Arthritis Rheum. 2012; 64: 1134-1144
        • Haroon M.
        • Winchester R.
        • Giles J.T.
        • et al.
        Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype.
        Ann Rheum Dis. 2014; ([Epub ahead of print])
        • Eder L.
        • Chandran V.
        • Pellet F.
        • et al.
        Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis.
        Ann Rheum Dis. 2012; 71: 50-55
        • Okada Y.
        • Han B.
        • Tsoi L.C.
        • et al.
        Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes.
        Am J Hum Genet. 2014; 95: 162-172
        • Gonzalez S.
        • Martinez-Borra J.
        • Torre-Alonso J.C.
        • et al.
        The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis.
        Arthritis Rheum. 1999; 42: 1010-1016
        • Lanier L.L.
        NK cell recognition.
        Annu Rev Immunol. 2005; 23: 225-274
        • Chandran V.
        • Bull S.B.
        • Pellett F.J.
        • et al.
        Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis.
        Rheumatology. 2014; 53: 233-239
        • O’Rielly D.D.
        • Rahman P.
        Genetics of susceptibility and treatment response in psoriatic arthritis.
        Nat Rev Rheumatol. 2011; 7: 718-732
        • Karason A.
        • Gudjonsson J.E.
        • Upmanyu R.
        • et al.
        A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting.
        Am J Hum Genet. 2003; 72: 125-131
        • Schroder J.M.
        • Harder J.
        Human beta-defensin-2.
        Int J Biochem Cell Biol. 1999; 31: 645-651
        • Hollox E.J.
        • Huffmeier U.
        • Zeeuwen P.L.
        • et al.
        Psoriasis is associated with increased β defensin genomic copy number.
        Nat Genet. 2008; 40: 23-25
        • Niyonsaba F.
        • Ogawa H.
        • Nagaoka I.
        Human β defensin 2 functions as a chemotactic agent for tumour necrosis factor α-treated human neutrophils.
        Immunology. 2004; 111: 273-281
        • Filer C.
        • Ho P.
        • Smith R.L.
        • et al.
        Investigation of association of the IL12B and IL23R genes with psoriatic arthritis.
        Arthritis Rheum. 2008; 58: 3705-3709
        • Li M.
        • Wu Y.
        • Chen G.
        • et al.
        Deletion of the late cornified envelope genes LCE3C and LCE3B is associated with psoriasis in a Chinese population.
        J Invest Dermatol. 2011; 131: 1639-1643
        • Coto E.
        • Santos-Juanes J.
        • Coto-Segura P.
        • et al.
        Mutation analysis of the LCE3B/LCE3C genes in Psoriasis.
        BMC Med Genet. 2010; 11: 45
        • Riveira-Munoz E.
        • He S.M.
        • Escaramís G.
        • et al.
        Meta-analysis confirms the LCE3C_LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6.
        J Invest Dermatol. 2011; 131: 1105-1109
        • Labarthe M.P.
        • Bosco D.
        • Saurat J.H.
        • et al.
        Upregulation of connexin 26 between keratinocytes of psoriatic lesions.
        J Invest Dermatol. 1998; 111: 72-76
        • Djalilian A.R.
        • McGaughey D.
        • Patel S.
        • et al.
        Connexin 26 regulates epidermal barrier and wound remodeling and promotes psoriasiform response.
        J Clin Invest. 2006; 116: 1243-1253
        • Sun L.D.
        • Cheng H.
        • Wang Z.X.
        • et al.
        Association analyses identify six new psoriasis susceptibility loci in the Chinese population.
        Nat Genet. 2010; 42: 1005-1009
        • Hüffmeier U.
        • Uebe S.
        • Ekici A.B.
        • et al.
        Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis.
        Nat Genet. 2010; 42: 996-999
        • Tsoi L.C.
        • Spain S.L.
        • Knight J.
        • et al.
        Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.
        Nat Genet. 2012; 44: 1341-1348
        • Ellinghaus D.
        • Ellinghaus E.
        • Nair R.P.
        • et al.
        Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci.
        Am J Hum Genet. 2012; 90: 636-647
        • Liu Y.
        • Helms C.
        • Liao W.
        • et al.
        A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci.
        PLoS Genet. 2008; 4: e1000041
        • Stuart P.E.
        • Nair R.P.
        • Ellinghaus E.
        • et al.
        Genome-wide association analysis identifies three psoriasis susceptibility loci.
        Nat Genet. 2010; 42: 1000-1004
        • Nair R.P.
        • Duffin K.C.
        • Helms C.
        • et al.
        Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways.
        Nat Genet. 2009; 41: 199-204
        • Ellinghaus E.
        • Ellinghaus D.
        • Stuart P.E.
        • et al.
        Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2.
        Nat Genet. 2010; 42: 991-995
        • Strange A.
        • Capon F.
        • Spencer C.C.
        • et al.
        A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.
        Nat Genet. 2010; 42: 985-990
        • Zhang X.J.
        • Huang W.
        • Yang S.
        • et al.
        Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21.
        Nat Genet. 2009; 41: 205-210
        • Verstrepen L.
        • Carpentier I.
        • Verhelst K.
        • et al.
        ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling.
        Biochem Pharmacol. 2009; 78: 105-114
        • Hayden M.S.
        • Ghosh S.
        NF κB in immunobiology.
        Cell Res. 2011; 21: 223-244
        • Orozco G.
        • Eyre S.
        • Hinks A.
        • et al.
        Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus.
        Ann Rheum Dis. 2011; 70: 463-468
        • Vereecke L.
        • Beyaert R.
        • van Loo G.
        Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease.
        Biochem Soc Trans. 2011; 39: 1086-1091
        • Nititham J.
        • Taylor K.E.
        • Gupta R.
        • et al.
        Meta-analysis of the TNFAIP3 region in psoriasis reveals a risk haplotype that is distinct from other autoimmune diseases.
        Genes Immun. 2015; 16: 120-126
        • De Molfetta G.A.
        • Lucíola Zanette D.
        • Alexandre Panepucci R.
        • et al.
        Role of NFKB2 on the early myeloid differentiation of CD34+ hematopoietic stem/progenitor cells.
        Differentiation. 2010; 80: 195-203
        • Lowenstein C.J.
        • Padalko E.
        iNOS (NOS2) at a glance.
        J Cell Sci. 2004; 117: 2865-2867
        • Strobl B.
        • Stoiber D.
        • Sexl V.
        • et al.
        Tyrosine kinase 2 (TYK2) in cytokine signaling and host immunity.
        Front Biosci. 2011; 16: 3214-3232
        • Blonska M.
        • Lin X.
        NF-κB signaling pathways regulated by CARMA family of scaffold proteins.
        Cell Res. 2011; 21: 55-70
        • Lu T.
        • Jackson M.W.
        • Wang B.
        • et al.
        Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65.
        Proc Natl Acad Sci U S A. 2010; 107: 46-51
        • Orian A.
        • Whiteside S.
        • Israël A.
        • et al.
        Ubiquitin-mediated processing of NF-kappa B transcriptional activator precursor p105. Reconstitution of a cell-free system and identification of the ubiquitin-carrier protein, E2, and a novel ubiquitin-protein ligase, E3, involved in conjugation.
        J Biol Chem. 1995; 270: 21707-21714
        • Zhou Z.
        • Hamming O.J.
        • Ank N.
        • et al.
        Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases.
        J Virol. 2007; 81: 7749-7758
        • Gotoh K.
        • Tanaka Y.
        • Nishikimi A.
        • et al.
        Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation.
        J Exp Med. 2010; 207: 721-730
        • Negishi H.
        • Osawa T.
        • Ogami K.
        • et al.
        A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity.
        Proc Natl Acad Sci U S A. 2008; 105: 20446-20451
        • Piganis R.A.
        • De Weerd N.A.
        • Gould J.A.
        • et al.
        Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2.
        J Biol Chem. 2011; 286: 33811-33818
        • Bijlmakers M.J.
        • Kanneganti S.K.
        • Barker J.N.
        • et al.
        Functional analysis of the RNF114 psoriasis susceptibility gene implicates innate immune responses to double-stranded RNA in disease pathogenesis.
        Hum Mol Genet. 2011; 20: 3129-3137
        • Veale D.J.
        • Barnes L.
        • Rogers S.
        • et al.
        Immunohistochemical markers for arthritis in psoriasis.
        Ann Rheum Dis. 1994; 53: 450-454
        • Pitzalis C.
        • Cauli A.
        • Pipitone N.
        • et al.
        Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis.
        Arthritis Rheum. 1996; 39: 137-145
        • Miossec P.
        IL-17 and Th17 cells in human inflammatory diseases.
        Microbes Infect. 2009; 11: 625-630
        • Bowcock A.M.
        • Shannon W.
        • Du F.
        • et al.
        Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies.
        Hum Mol Genet. 2001; 10: 1793-1805
        • Kersh E.N.
        Impaired memory CD8 T cell development in the absence of methyl-CpG-binding domain protein 2.
        J Immunol. 2006; 177: 3821-3826
        • Zamisch M.
        • Tian L.
        • Grenningloh R.
        • et al.
        The transcription factor Ets1 is important for CD4 repression and Runx3 up-regulation during CD8 T cell differentiation in the thymus.
        J Exp Med. 2009; 206: 2685-2699
        • Chang I.F.
        • Hsiao H.Y.
        Induction of RhoGAP and pathological changes characteristic of Alzheimer's disease by UAHFEMF discharge in rat brain.
        Curr Alzheimer Res. 2005; 2: 559-569
        • Togayachi A.
        • Kozono Y.
        • Kuno A.
        • et al.
        Beta3GnT2 (B3GNT2), a major polylactosamine synthase: analysis of B3GNT2-deficient mice.
        Methods Enzymol. 2010; 479: 185-204
        • Yan J.
        • Parekh V.V.
        • Mendez-Fernandez Y.
        • et al.
        In vivo role of ER associated peptidase activity in tailoring peptides for presentation by MHC class Ia and class Ib molecules.
        J Exp Med. 2006; 203: 647-659
        • Ryan C.
        • Abramson A.
        • Patel M.
        • et al.
        Current investigational drugs in psoriasis.
        Expert Opin Investig Drugs. 2012; 21: 473-487
        • Liang J.
        • Wang J.
        • Azfer A.
        • et al.
        A novel CCCH-zinc finger protein family regulates proinflammatory activation of macrophages.
        J Biol Chem. 2008; 283: 6337-6346
        • Robinson R.T.
        IL12Rβ1: the cytokine receptor that we used to know.
        Cytokine. 2015; 71: 348-359
        • Wei L.
        • Laurence A.
        • O'Shea J.J.
        New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation.
        Semin Cell Dev Biol. 2008; 19: 394-400
        • Marcoulatos P.
        • Avgerinos E.
        • Tsantzalos D.V.
        • et al.
        Mapping interleukin enhancer binding factor 3 gene (ILF3) to human chromosome 19 (19q11-qter and 19p11-p13.1) by polymerase chain reaction amplification of human-rodent somatic cell hybrid DNA templates.
        J Interferon Cytokine Res. 1998; 18: 351-355
        • Cheung P.F.
        • Wong C.K.
        • Lam C.W.
        Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation.
        J Immunol. 2008; 180: 5625-5635
        • Bulek K.
        • Liu C.
        • Swaidani S.
        • et al.
        The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation.
        Nat Immunol. 2011; 12: 844-852
        • Sønder S.U.
        • Saret S.
        • Tang W.
        • et al.
        IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms.
        J Biol Chem. 2011; 286: 12881-12890
        • Fujioka S.
        • Niu J.
        • Schmidt C.
        • et al.
        NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity.
        Mol Cell Biol. 2004; 24: 7806-7819
        • Chiricozzi A.
        • Guttman-Yassky E.
        • Suárez-Fariρas M.
        • et al.
        Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis.
        J Invest Dermatol. 2011; 131: 677-687
        • Zaba L.C.
        • Suárez-Fariñas M.
        • Fuentes-Duculan J.
        • et al.
        Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.
        J Allergy Clin Immunol. 2009; 124: 1022-1030
        • Tesmer L.A.
        • Lundy S.K.
        • Sarkar S.
        • et al.
        Th17 cells in human disease.
        Immunol Rev. 2008; 223: 87-113
        • Flisiak I.
        • Chodynicka B.
        • Porebski P.
        • et al.
        Association between psoriasis severity and transforming growth factor beta(1) and beta (2) in plasma and scales from psoriatic lesions.
        Cytokine. 2002; 19: 121-125
        • Flisiak I.
        • Zaniewski P.
        • Chodynicka B.
        Plasma TGF-beta1, TIMP-1, MMP-1 and IL-18 as a combined biomarker of psoriasis activity.
        Biomarkers. 2008; 13: 549-556
        • Nockowski P.
        • Szepietowski J.C.
        • Ziarkiewicz M.
        • et al.
        Serum concentrations of transforming growth factor beta 1 in patients with psoriasis vulgaris.
        Acta Dermatovenerol Croat. 2004; 12: 2-6
        • Lindroos J.
        • Svensson L.
        • Norsgaard H.
        • et al.
        IL-23-mediated epidermal hyperplasia is dependent on IL-6.
        J Invest Dermatol. 2011; 131: 1110-1118
        • Yang X.P.
        • Ghoreschi K.
        • Steward-Tharp S.M.
        • et al.
        Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5.
        Nat Immunol. 2011; 12: 247-254
        • Boca A.N.
        • Talamonti M.
        • Galluzzo M.
        • et al.
        Genetic variations in IL6 and IL12B decreasing the risk for psoriasis.
        Immunol Lett. 2013; 156: 127-131
        • Di Cesare A.
        • Di Meglio P.
        • Nestle F.O.
        The IL-23/Th17 axis in the immunopathogenesis of psoriasis.
        J Invest Dermatol. 2009; 129: 1339-1350
        • Korn T.
        • Bettelli E.
        • Oukka M.
        • et al.
        IL-17 and Th17 Cells.
        Annu Rev Immunol. 2009; 27: 485-517
        • Blumberg H.
        • Dinh H.
        • Dean Jr., C.
        • et al.
        IL-1RL2 and its ligands contribute to the cytokine network in psoriasis.
        J Immunol. 2010; 185: 4354-4362
        • Julià A.
        • Tortosa R.
        • Hernanz J.M.
        • et al.
        Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes.
        Hum Mol Genet. 2012; 21: 4549-4557
        • Rahman P.
        • Sun S.
        • Peddle L.
        • et al.
        Association between the interleukin-1 family gene cluster and psoriatic arthritis.
        Arthritis Rheum. 2006; 54: 2321-2325
        • Ravindran J.S.
        • Owen P.
        • Lagan A.
        • et al.
        Interleukin 1alpha, interleukin 1beta and interleukin 1 receptor gene polymorphisms in psoriatic arthritis.
        Rheumatology (Oxford). 2004; 43: 22-26
        • Bowes J.
        • Ho P.
        • Flynn E.
        • et al.
        Investigation of IL1, VEGF, PPARG and MEFV genes in psoriatic arthritis susceptibility.
        Ann Rheum Dis. 2012; 71: 313-314
        • Oppmann B.
        • Lesley R.
        • Blom B.
        • et al.
        Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.
        Immunity. 2000; 13: 715-725
        • Pappu R.
        • Ramirez-Carrozzi V.
        • Sambandam A.
        The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases.
        Immunology. 2011; 134: 8-16
        • Szodoray P.
        • Alex P.
        • Chappell-Woodward C.M.
        • et al.
        Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system.
        Rheumatology (Oxford). 2007; 46: 417-425
        • Lee E.
        • Trepicchio W.L.
        • Oestreicher J.L.
        • et al.
        Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.
        J Exp Med. 2004; 199: 125-130
        • Tang C.
        • Chen S.
        • Qian H.
        • et al.
        Interleukin-23: as a drug target for autoimmune inflammatory diseases.
        Immunology. 2012; 135: 112-124
        • Langrish C.L.
        • Chen Y.
        • Blumenschein W.M.
        • et al.
        IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.
        J Exp Med. 2005; 201: 233-240
        • Harris T.J.
        • Grosso J.F.
        • Yen H.R.
        • et al.
        Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity.
        J Immunol. 2007; 179: 4313-4317
        • Tanaka K.
        • Ichiyama K.
        • Hashimoto M.
        • et al.
        Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads.
        J Immunol. 2008; 180: 3746-3756
        • Moisan J.
        • Grenningloh R.
        • Bettelli E.
        • et al.
        Ets-1 is a negative regulator of Th17 differentiation.
        J Exp Med. 2007; 204: 2825-2835
        • Novatchkova M.
        • Leibbrandt A.
        • Werzowa J.
        • et al.
        The STIR-domain superfamily in signal transduction, development and immunity.
        Trends Biochem Sci. 2003; 28: 226-229
        • Toy D.
        • Kugler D.
        • Wolfson M.
        • et al.
        Cutting edge: interleukin 17 signals through a heteromeric receptor complex.
        J Immunol. 2006; 177: 36-39
        • Lubberts E.
        IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?.
        Cytokine. 2008; 41: 84-91
        • Chabaud M.
        • Lubberts E.
        • Joosten L.
        • et al.
        IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis.
        Arthritis Res. 2001; 3: 168-177
        • Raychaudhuri S.P.
        • Raychaudhuri S.K.
        • Genovese M.C.
        IL-17 receptor and its functional significance in psoriatic arthritis.
        Mol Cell Biochem. 2012; 359: 419-429
        • Mrabet D.
        • Laadhar L.
        • Sahli H.
        • et al.
        Synovial fluid and serum levels of IL-17, IL-23, and CCL-20 in rheumatoid arthritis and psoriatic arthritis: a Tunisian cross-sectional study.
        Rheumatol Int. 2013; 33: 265-266
        • Tonel G.
        • Conrad C.
        • Laggner U.
        • et al.
        Cutting edge: a critical functional role for IL-23 in psoriasis.
        J Immunol. 2010; 185: 5688-5691
        • Wilson N.J.
        • Boniface K.
        • Chan J.R.
        • et al.
        Development, cytokine profile and function of human interleukin 17-producing helper T cells.
        Nat Immunol. 2007; 8: 950-957
        • Feinberg M.W.
        • Cao Z.
        • Wara A.K.
        • et al.
        Kruppel-like factor 4 is a mediator of proinflammatory signaling in macrophages.
        J Biol Chem. 2005; 280: 38247-38258
        • Huber M.
        • Brüstle A.
        • Reinhard K.
        • et al.
        IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype.
        Proc Natl Acad Sci U S A. 2008; 105: 20846-20851
        • Ammar M.
        • Bouchlaka-Souissi C.
        • Zaraa I.
        • et al.
        Family-based association study in Tunisian familial psoriasis.
        Int J Dermatol. 2012; 51: 1329-1334
        • Catanoso M.G.
        • Boiardi L.
        • Macchioni P.
        • et al.
        IL-23A, IL-23R, IL-17A and IL-17R polymorphisms in different psoriatic arthritis clinical manifestations in the northern Italian population.
        Rheumatol Int. 2013; 33: 1165-1176
        • Prans E.
        • Kingo K.
        • Traks T.
        • et al.
        Copy number variations in IL22 gene are associated with Psoriasis vulgaris.
        Hum Immunol. 2013; 74: 792-795
        • Tohyama M.
        • Hanakawa Y.
        • Shirakata Y.
        • et al.
        IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression.
        Eur J Immunol. 2009; 39: 2779-2788
        • Saeki H.
        • Hirota T.
        • Nakagawa H.
        • et al.
        Genetic polymorphisms in the IL22 gene are associated with psoriasis vulgaris in a Japanese population.
        J Dermatol Sci. 2013; 71: 148-150
        • Yang X.O.
        • Pappu B.P.
        • Nurieva R.
        • et al.
        T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma.
        Immunity. 2008; 28: 29-39
        • Korn T.
        • Bettelli E.
        • Gao W.
        • et al.
        IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells.
        Nature. 2007; 448: 484-487
        • Nurieva R.
        • Yang X.O.
        • Martinez G.
        • et al.
        Essential autocrine regulation by IL-21 in the generation of inflammatory T cells.
        Nature. 2007; 448: 480-483
        • Caruso R.
        • Botti E.
        • Sarra M.
        • et al.
        Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis.
        Nat Med. 2009; 15: 1013-1015
        • He Z.
        • Jin L.
        • Liu Z.F.
        • et al.
        Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis.
        Br J Dermatol. 2012; 167: 191-193
        • Warren R.B.
        • Smith R.L.
        • Flynn E.
        • et al.
        A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21.
        Br J Dermatol. 2011; 164: 660-664
        • Bowes J.
        • Orozco G.
        • Flynn E.
        • et al.
        Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis.
        Ann Rheum Dis. 2011; 70: 1641-1644
        • Zhu K.J.
        • Zhu C.Y.
        • Shi G.
        • et al.
        Association of IL23R polymorphisms with psoriasis and psoriatic arthritis: a meta-analysis.
        Inflamm Res. 2012; 61: 1149-1154
        • Cénit M.C.
        • Ortego-Centeno N.
        • Raya E.
        • et al.
        Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behcet's disease.
        Hum Immunol. 2013; 74: 230-233
        • Leipe J.
        • Grunke M.
        • Dechant C.
        • et al.
        Role of Th17 cells in human autoimmune arthritis.
        Arthritis Rheum. 2010; 62: 2876-2885
        • van Kuijk A.W.
        • Reinders-Blankert P.
        • Smeets T.J.
        • et al.
        Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment.
        Ann Rheum Dis. 2006; 65: 1551-1557
        • Yago T.
        • Nanke Y.
        • Kawamoto M.
        • et al.
        IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats.
        Arthritis Res Ther. 2007; 9: R96
        • Gottlieb A.
        • Menter A.
        • Mendelsohn A.
        • et al.
        Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
        Lancet. 2009; 373: 633-640
        • Gervin K.
        • Vigeland M.D.
        • Mattingsdal M.
        • et al.
        DNA methylation and gene expression changes in monozygotic twins discordant for psoriasis: identification of epigenetically dysregulated genes.
        PLoS Genet. 2012; 8: e1002454
        • Gudjonsson J.E.
        • Krueger G.
        A role for epigenetics in psoriasis: methylated Cytosine-Guanine sites differentiate lesional from nonlesional skin and from normal skin.
        J Invest Dermatol. 2012; 132: 506-508
        • Duffin K.C.
        • Freeny I.C.
        • Schrodi S.J.
        • et al.
        Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking.
        J Invest Dermatol. 2009; 129: 2777-2783
        • Eder L.
        • Chandran V.
        • Pellett F.
        • et al.
        IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients.
        Ann Rheum Dis. 2011; 70: 1594-1598
        • Chatterjee R.
        • Vinson C.
        CpG methylation recruits sequence specific transcription factors essential for tissue specific gene expression.
        Biochim Biophys Acta. 2012; 1819: 763-770
        • Zhang P.
        • Su Y.
        • Chen H.
        • et al.
        Abnormal DNA methylation in skin lesions and PBMCs of patients with psoriasis vulgaris.
        J Dermatol Sci. 2010; 60: 40-42
        • Han J.
        • Park S.G.
        • Bae J.B.
        • et al.
        The characteristics of genome-wide DNA methylation in naïve CD4+ T cells of patients with psoriasis or atopic dermatitis.
        Biochem Biophys Res Commun. 2012; 422: 157-163
        • Roberson E.D.
        • Liu Y.
        • Ryan C.
        • et al.
        A subset of methylated CpG sites differentiate psoriatic from normal skin.
        J Invest Dermatol. 2012; 132: 583-592
        • Gu X.
        • Nylander E.
        • Coates P.J.
        • et al.
        Correlation between reversal of DNA methylation and clinical symptoms in psoriatic epidermis following narrow-band UVB phototherapy.
        J Invest Dermatol. 2015; 135: 2077-2083
        • Hou R.
        • Yin G.
        • An P.
        • et al.
        DNA methylation of dermal MSCs in psoriasis: identification of epigenetically dysregulated genes.
        J Dermatol Sci. 2013; 72: 103-109
        • Zhang P.
        • Zhao M.
        • Liang G.
        • et al.
        Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris.
        J Autoimmun. 2013; 41: 17-24
        • Park G.T.
        • Han J.
        • Park S.G.
        • et al.
        DNA methylation analysis of CD4+ T cells in patients with psoriasis.
        Arch Dermatol Res. 2014; 306: 259-268
        • Mizutani H.
        • Ohmoto Y.
        • Mizutani T.
        • et al.
        Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments.
        J Dermatol Sci. 1997; 14: 145-153
        • Anandarajah A.
        • Ritchlin C.T.
        Treatment update on spondyloarthropathy.
        Curr Opin Rheumatol. 2005; 17: 247-256
        • Gottlieb A.B.
        • Leonardi C.L.
        • Goffe B.S.
        • et al.
        Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database.
        J Am Acad Dermatol. 2006; 54: S92-S100
        • Krueger G.G.
        • Langley R.G.
        • Finlay A.Y.
        • et al.
        Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
        Br J Dermatol. 2005; 153: 1192-1199
        • Moore A.
        • Gordon K.B.
        • Kang S.
        • et al.
        A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
        J Am Acad Dermatol. 2007; 56: 598-603
        • Gottlieb A.B.
        • Masud S.
        • Ramamurthi R.
        • et al.
        Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris.
        J Am Acad Dermatol. 2003; 48: 68-75
        • Menter A.
        • Gottlieb A.
        • Feldman S.R.
        • et al.
        Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
        J Am Acad Dermatol. 2008; 58: 826-850
        • Menter A.
        • Tyring S.K.
        • Gordon K.
        • et al.
        Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial.
        J Am Acad Dermatol. 2007; 58: 106-115
        • Seitz M.
        • Wirthmüller U.
        • Möller B.
        • et al.
        The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
        Rheumatology (Oxford). 2007; 46: 93-96
        • Murdaca G.
        • Gulli R.
        • Spanò F.
        • et al.
        TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis.
        J Invest Dermatol. 2014; 134: 2503-2509
        • Morales-Lara M.J.
        • Cañete J.D.
        • Torres-Moreno D.
        • et al.
        Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
        Joint Bone Spine. 2012; 79: 591-596
        • Pundt N.
        • Peters M.A.
        • Wunrau C.
        • et al.
        Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL- and TRAIL-induced apoptosis is cell cycle-dependent.
        Arthritis Res Ther. 2009; 11: R16
        • Hofbauer L.C.
        • Schoppet M.
        • Christ M.
        • et al.
        Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis.
        Rheumatology (Oxford). 2006; 45: 1218-1222
        • Batalla A.
        • Coto E.
        • González-Fernández D.
        • et al.
        The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients.
        Pharmacogenet Genomics. 2015; 25: 313-316
        • Ramírez J.
        • Fernández-Sueiro J.L.
        • López-Mejías R.
        • et al.
        FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.
        J Rheumatol. 2012; 39: 1035-1041
        • Gottlieb A.B.
        • Chamian F.
        • Masud S.
        • et al.
        TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.
        J Immunol. 2005; 175: 2721-2729
        • Krueger G.G.
        • Langley R.G.
        • Leonardi C.
        • et al.
        A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
        N Engl J Med. 2007; 356: 580-592
        • Chien A.L.
        • Elder J.T.
        • Ellis C.N.
        Ustekinumab: a new option in psoriasis therapy.
        Drugs. 2009; 69: 1141-1152
        • Chen X.
        • Tan Z.
        • Yue Q.
        • et al.
        The expression of interleukin-23 (p19/p40) and inteleukin-12 (p35/p40) in psoriasis skin.
        J Huazhong Univ Sci Technolog Med Sci. 2006; 26: 750-752
        • Talamonti M.
        • Botti E.
        • Galluzzo M.
        • et al.
        Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.
        Br J Dermatol. 2013; 169: 458-463
        • Baerveldt E.M.
        • Onderdijk A.J.
        • Kurek D.
        • et al.
        Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
        Br J Dermatol. 2013; 168: 990-998
        • Gedebjerg A.
        • Johansen C.
        • Kragballe K.
        • et al.
        IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab.
        Acta Derm Venereol. 2013; 93: 150-155